WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company’s President and Chief Executive Officer, Tod Woolf, Ph.D., will present an industry keynote address at the seventh annual RNAi, MicroRNAs - 2009 - Boston Meeting on Wednesday, April 1, 2009.
